Sildenafil Citrate Orodispersible Tablet – Huiren / Likexin 50mg

Description Contents hide 1 Product Specifications 2 Mechanism of Action 3 Research Applications & Pharmacology 4 Safety Profile & Handling Product SpecificationsAttributeDetailsProduct NameSildenafil Citrate Orodispersible Tablet (Huiren® / Likexin)Generic NameSildenafil CitrateCAS Number171599-83-0Molecular FormulaC22 H3o N604S. CH807 (or C28 H38 N6011S)Molecular Weight666.70 g/molDosage FormOrodispersible tablet (ODT)Strength50mg per tabletPack Size1 tablet per boxApproval NumberChina NMPA H20244673Product Code86910323000369ManufacturerJiangxi Huiren Pharmaceutical Co., Ltd.Barcode6937999607160StorageStore at 15–25°C; protect from light and moistureIntended UseLaboratory research onlyMechanism of ActionSildenafil selectively inhibits PDE5, preventing breakdown of cGMP in smooth muscle cells, leading to enhanced nitric oxide (NO)-mediated vasodilation, especially in penile and pulmonary vasculature.Research Applications & PharmacologyErectile Dysfunction (ED) Models: Widely used to assess cGMP-mediated signaling and vascular responses .Pulmonary Arterial Hypertension: Employed to investigate PDE5’s role in pulmonary vascular dilation.Pharmacokinetics of ODTs: Orodispersible formulations dissolve rapidly in seconds—promoting fast absorption without water .Clinical Parameters: Typical onset ~20 minutes, duration ~2 hours; metabolic clearance by CYP3A4/5; excreted primarily in feces and urine .Safety Profile & HandlingCommon Adverse Effects: Headache, flushing, nasal congestion, dyspepsia, and mild dizziness .Drug Interactions: Avoid concurrent administration with nitrates or NO donors due to risk of severe hypotension .Contraindications: Not suitable for models involving cardiovascular compromise or concurrent PDE5-inhibiting agents.Handling Instructions: Store under recommended conditions, use protective PPE, discard as per institutional safety protocols. This product is strictly for research and not for administration.